Literatur
- 1 Katsarava Z, Diener H-C.
Medikamenteninduzierter Kopfschmerz. In: Diener H-C (Hrsg) Kopfschmerzen. Stuttgart, New York; Thieme 2003
- 2
Rosenzweig P S, Brohier A, Zipfel A.
The placebo effect in healthy volunteers: influence of experimental conditions on
the adverse events profile during phase I studies.
Clin Pharmacol Ther.
1993;
54
578-583
- 3
Lassen L H. et al .
Histamine-1 receptor blockade does not prevent nitroglycerin induced migraine. Support
for the NO-hypothesis of migraine.
Eur J Clin Pharmacol.
1996;
49
335-339
- 4 Monteiro J M, Dahlof C G.
Single use of substances. In: Olesen J, Tfelt-Hansen P, Welch KM (eds) The Headaches. Philadelphia; Lippincott
Williams & Wilkins 2001: 861-869
- 5
Internationale Kopfschmerzgesellschaft (IHS) (Hrsg) .
Internationale Klassifikation der Kopfschmerzen. 2. Auflage.
Nervenheilkunde.
2003;
22
531-670
- 6
Iversen H K, Olesen J, Tfelt-Hansen P.
Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics.
Pain.
1989;
38
17-24
- 7
Fink H A. et al .
Sildenafil for male erectile dysfunction: a systematic review and meta-analysis.
Arch Intern Med.
2002;
162
1349-1360
- 8
Kruuse C. et al .
The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow
or blood velocity, but nevertheless induces headache in healthy subjects.
J Cereb Blood Flow Metab.
2002;
22
1124-1131
- 9
Lassen L H. et al .
CGRP may play a causative role in migraine.
Cephalalgia.
2002;
22
54-61
- 10
Dalton K.
Migraine and oral contraceptives.
Headache.
1976;
15
247-251
- 11
Ashina M. et al .
Glyceryl trinitrate may trigger endogenous nitric oxide production in patients with
chronic tension-type headache.
Cephalalgia.
2004;
24
967-972
- 12
Ekbom K.
Nitroglycerin as a provocative agent in cluster headache.
Arch Neurol.
1968;
19
487-493
- 13
Askmark H, Lundberg P O, Olsson S.
Drug-related headache.
Headache.
1989;
29
441-444
- 14
Robson R H.
Recurrent migraine after propranolol.
Br Heart J.
1977;
39
1157-1158
- 15
Zsoter T T, Church J G.
Calcium antagonists. Pharmacodynamic effects and mechanism of action.
Drugs.
1983;
25
93-112
- 16
Saint-Martin F. et al .
A randomized, double-blind, parallel-group study, comparing the efficacy and safety
of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist,
to loratadine 10 mg in the treatment of seasonal allergic rhinitis.
J Investig Allergol Clin Immunol.
2004;
14
34-40
- 17
Piper D W.
A comparative overview of the adverse effects of antiulcer drugs.
Drug Saf.
1995;
12
120-138
- 18
Sierra A de la. et al .
Comparison of the antihypertensive effects of the fixed dose combination enalapril
10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by
24-h ambulatory blood pressure monitoring, in essential hypertensive patients.
J Hum Hypertens.
2004;
18
215-222
- 19
Derbes S J.
Trimethoprim-induced aseptic meningitis.
JAMA.
1984;
252
2865-2866
- 20
Lindgren A. et al .
Dipyridamole and headache - a pilot study of initial dose titration.
J Neurol Sci.
2004;
223
179-184
- 21
Olesen J. et al .
Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment
of migraine.
N Engl J Med.
2004;
350
1104-1110
- 22
Bartsch T, Goadsby P J.
Increased responses in trigeminocervical nociceptive neurons to cervical input after
stimulation of the dura mater.
Brain.
2003;
126
1801-1813
- 23
Goadsby P J, Lipton R B, Ferrari M D.
Migraine - current understanding and treatment.
N Engl J Med.
2002;
346
257-270
- 24
Garthwaite J, Boulton C L.
Nitric oxide signaling in the central nervous system.
Annu Rev Physiol.
1995;
57
683-706
- 25
Ashwath M L, Katner H P.
Recurrent aseptic meningitis due to different non-steroidal anti-inflammatory drugs
including rofecoxib.
Postgrad Med J.
2003;
79
295-296
- 26
Forderreuther S, Straube A.
Indomethacin reduces CSF pressure in intracranial hypertension.
Neurology.
2000;
55
1043-1045
- 27
Slavik R S, Rhoney D H.
Indomethacin: a review of its cerebral blood flow effects and potential use for controlling
intracranial pressure in traumatic brain injury patients.
Neurol Res.
1999;
21
491-499
- 28
Eisenberg E. et al .
Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study.
Neurology.
2001;
57
505-509
- 29
Schweiger A, Parducci A.
Nocebo: the psychologic induction of pain.
Pavlov J Biol Sci.
1981;
16
140-143
- 30
Wager T D. et al .
Placebo-induced changes in FMRI in the anticipation and experience of pain.
Science.
2004;
303
1162-1167
- 31
Cleophas T J, Niemeyer M G, Wall E E van Der.
Nitrate-Induced Headache in Patients with Stable Angina Pectoris: Beneficial Effect
of Starting on a Low Dosage.
Am J Ther.
1996;
3
802-806
- 32 Goadsby P J.
Headache associated with acute substance use or exposure. In: Gilman S, Goldstein GW, Waxman SG (eds) Neurobase. San Diego; Arbor Publisher
1998
- 33
Castillo J. et al .
Epidemiology of chronic daily headache in the general population.
Headache.
1999;
39
190-196
- 34
Scher A I. et al .
Prevalence of frequent headache in a population sample.
Headache.
1998;
38
497-506
- 35
Colas R. et al .
Chronic daily headache with analgesic overuse: epidemiology and impact on quality
of life.
Neurology.
2004;
62
1338-1342
- 36
Lanteri-Minet M. et al .
Prevalence and description of chronic daily headache in the general population in
France.
Pain.
2003;
102
143-149
- 37
Wang S J. et al .
Chronic daily headache in Chinese elderly: prevalence, risk factors, and biannual
follow-up.
Neurology.
2000;
54
314-319
- 38
Rapoport A. et al .
Analgesic rebound headache in clinical practice: data from a physician survey.
Headache.
1996;
36
14-19
- 39
Gaist D.
Use and overuse of sumatriptan. Pharmaco-epidemiological studies based on prescription
register and interview data.
Cephalalgia.
1999;
19
735-761
- 40
Lucas C. et al .
Use and misuse of triptans in France: data from the GRIM2000 population survey.
Cephalalgia.
2004;
24
197-205
- 41
Limmroth V. et al .
Features of medication overuse headache following overuse of different acute headache
drugs.
Neurology.
2002;
59
1011-1014
- 42
Zwart J A. et al .
Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT
Study.
Neurology.
2003;
61
160-164
- 43
Scher A I. et al .
Factors associated with the onset and remission of chronic daily headache in a population-based
study.
Pain.
2003;
106
81-89
- 44
Katsarava Z. et al .
Incidence and predictors for chronicity of headache in patients with episodic migraine.
Neurology.
2004;
62
788-790
- 45
Bahra A. et al .
Does chronic daily headache arise de novo in association with regular use of analgesics?.
Headache.
2003;
43
179-190
- 46 Diener H C, Dahlöf C GH.
Headache associated with chronic use of substances. In: Olesen J, Tfelt-Hansen P, Welch KMA (eds) The Headaches. 2nd edition. Philadelphia; Lippincott, Williams & Wilkins 1999: 871-878
- 47
Gobel H. et al .
Easy therapeutical management of sumatriptan-induced daily headache.
Neurology.
1996;
47
297-298
- 48
Katsarava Z. et al .
Clinical features of withdrawal headache following overuse of triptans and other headache
drugs.
Neurology.
2001;
57
1694-1698
- 49
Mathew N T.
Amelioration of ergotamine withdrawal symptoms with naproxen.
Headache.
1987;
27
130-133
- 50
Raskin N H.
Repetitive intravenous dihydroergotamine as therapy for intractable migraine.
Neurology.
1986;
36
995-997
- 51
Diener H C. et al .
Subcutaneous sumatriptan in the treatment of headache during withdrawal from drug-induced
headache.
Headache.
1990;
31
205-209
- 52
Krymchantowski A V, Barbosa J S.
Prednisone as initial treatment of analgesic-induced daily headache.
Cephalalgia.
2000;
20
107-113
- 53
Pini L. et al .
Headaches associated with chronic use of analgesics: a theraputic approach.
Headache.
1996;
36
433-439
- 54
Linton-Dahlof P, Linde M, Dahlof C.
Withdrawal therapy improves chronic daily headache associated with long-term misuse
of headache medication: a retrospective study.
Cephalalgia.
2000;
20
658-662
- 55
Baumgartner C. et al .
Long-term prognosis of analgesic withdrawal in patients with drug-induced headaches.
Headache.
1989;
29
510-514
- 56
Schnider P. et al .
Long-term outcome of patients with headache and drug abuse after inpatient withdrawal:
five year follow-up.
Cephalalgia.
1996;
16
481-485
- 57
Diener H C. et al .
Analgesic-induced chronic headache: long-term results of withdrawal therapy.
J Neurol.
1989;
236
9-14
- 58
Fritsche G. et al .
Drug-induced headache: long-term follow-up of withdrawal therapy and persistence of
drug misuse.
Eur Neurol.
2001;
45
229-235
- 59
Katsarava Z. et al .
Rates and predictors for relapse in medication overuse headache: a 1-year prospective
study.
Neurology.
2003;
60
1682-1683
- 60
Katsarava Z. et al .
Medication overuse headache: rates and predictors for relapse in a 4-year prospective
study.
Cephalalgia.
2005;
25
12-15
- 61
Pini L A, Cicero A FG, Sandrini M.
Long-term follow-up of patients treated for chronic headache with analgesic overuse.
Cephalalgia.
2001;
21
878-883
- 62
Tribl G G. et al .
Are there predictive factors for long-term outcome after withdrawal in drug-induced
chronic daily headache?.
Cephalalgia.
2001;
21
691-696
Dr. Thorsten Bartsch
Klinik für Neurologie der Universität Kiel · Neurozentrum
Schittenhelmstraße 10
24105 Kiel
Email: t.bartsch@neurologie.uni-kiel.de
